Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab

Overview of attention for article published in Dermatology and Therapy, February 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 36 Dimensions

Readers on

mendeley: 67 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 6,471 followers.

RT @DermatolTher: One of the journals most downloaded papers of 2018 evaluated the capacity of IL-17A selective antibodies to induce anti-d…

12 Jun 2018

Reply Repost Favourite

One of the journals most downloaded papers of 2018 evaluated the capacity of IL-17A selective antibodies to induce anti-drug related T cell response #invitro and confirming the immunogenicty potential of secukinumab. #Dermatology #psoriasis https://t.co/Dm

11 Jun 2018

Reply Repost Favourite

Looking beyond antidrug antibodies to evaluate the immunogenicity of biologics - cd4 t-cell assays https://t.co/6EZBo5l9hm https://t.co/N0nid4UGWT

11 Feb 2018

Reply Repost Favourite

Just published: Secukinumab demonstrates significantly lower immunogenicity potential compared to Ixekizumab. See the full article here https://t.co/y0utAB5xhH #Psoriasis #Dermatology https://t.co/R4gqy3PUE8

06 Feb 2018

Reply Repost Favourite